Last update 01 Apr 2025

Fingolimod Hydrochloride

Overview

Basic Info

Drug Type
Small molecule drug
Synonyms
FINGOLIMOD, Fingolimod hydrochloride (JAN/USAN), Gilenia
+ [11]
Action
modulators
Mechanism
EDG6 modulators(Sphingosine 1-phosphate receptor Edg-6 modulators), S1PR1 modulators(Sphingosine 1-phosphate receptor Edg-1 modulators), S1PR3 modulators(Sphingosine 1-phosphate receptor Edg-3 modulators)
Originator Organization
Inactive Organization-
Drug Highest PhaseApproved
First Approval Date
United States (21 Sep 2010),
RegulationOrphan Drug (United States), Orphan Drug (European Union), Priority Review (China), Orphan Drug (South Korea), Overseas New Drugs Urgently Needed in Clinical Settings (China), Breakthrough Therapy (United States), Orphan Drug (Japan)
Login to view timeline

Structure/Sequence

Molecular FormulaC19H34ClNO2
InChIKeySWZTYAVBMYWFGS-UHFFFAOYSA-N
CAS Registry162359-56-0

External Link

R&D Status

Approved
10 top approved records.
Login
to view more data
IndicationCountry/LocationOrganizationDate
Multiple Sclerosis, Relapsing-Remitting
European Union
17 Mar 2011
Multiple Sclerosis, Relapsing-Remitting
Iceland
17 Mar 2011
Multiple Sclerosis, Relapsing-Remitting
Liechtenstein
17 Mar 2011
Multiple Sclerosis, Relapsing-Remitting
Norway
17 Mar 2011
Multiple Sclerosis
Australia
01 Feb 2011
Multiple sclerosis relapse
United States
21 Sep 2010
Developing
10 top R&D records.
Login
to view more data
IndicationHighest PhaseCountry/LocationOrganizationDate
Influenza, HumanPhase 3
Belgium
01 Aug 2010
Influenza, HumanPhase 3
Canada
01 Aug 2010
Influenza, HumanPhase 3
Finland
01 Aug 2010
Influenza, HumanPhase 3
France
01 Aug 2010
Influenza, HumanPhase 3
Guatemala
01 Aug 2010
Influenza, HumanPhase 3
Poland
01 Aug 2010
Influenza, HumanPhase 3
Spain
01 Aug 2010
Influenza, HumanPhase 3
Switzerland
01 Aug 2010
Influenza, HumanPhase 3
United Kingdom
01 Aug 2010
Multiple Sclerosis, Primary ProgressivePhase 3
United States
28 Jul 2008
Login to view more data

Clinical Result

Indication
Phase
Evaluation
View All Results
Study
Phase
PopulationAnalyzed EnrollmentGroupResultsEvaluationPublication Date
Early Phase 1
28
(Fingolimod)
btenakjayx = wjumnlmrgr upomfoizof (ljmehdvmll, bdkokgjlef - fcxfahujkt)
-
25 Mar 2025
(Open-label Fingolimod)
btenakjayx = lkojouuzun upomfoizof (ljmehdvmll, qbntcekfkv - dmppxkwcvk)
Not Applicable
lymphopenia | hypertransaminasemia
50
wzmwerlbbm(egbvhpoawy) = cppbzofodk vzunesftgv (qrvvznybwn )
Positive
28 Jun 2024
yewpjtfikh(hhuqhlpbee) = puttgwhcvj jzxmsbdmyl (hafbbyovgf )
Not Applicable
31
(Rebound group)
mwuyqyyomw(fbecmukekl) = ourrrjwnmu smzywuoigl (jlujregqsw )
Positive
09 Apr 2024
(Non-rebound group)
mwuyqyyomw(fbecmukekl) = dnpgqbdcta smzywuoigl (jlujregqsw )
Not Applicable
350
suajsqamie(whgvtqdchj) = A 39-year-old woman with RRMS since 2003 presented changes in a nevus on her right foot sole in July 2018. It was excised in November 2018, with a report indicating melanocytic proliferation with atypia. Fingolimod was discontinued, and an autologous bone marrow transplant was performed in 2019. She is currently free of disease activity and skin lesions. A 32-year-old man with RRMS since 2010 reported heartburn and regurgitation in November 2018. Laboratory tests showed aspartate aminotransferase at 19, alanine aminotransferase at 42, and gamma-glutamyl transferase at 97, with no other abnormalities. An endoscopy and biopsy revealed a 2.8 cm subepithelial lesion in the cardia, consistent with leiomyoma. He is currently asymptomatic and continues fingolimod therapy. A 35-year-old woman with Diabetes Mellitus and RRMS since 2015, treated with fingolimod since 2018, developed a skin lesion in 2022. Histopathological examination confirmed cutaneous tuberculosis. Antimicrobial management was initiated without discontinuing fingolimod. The skin lesion has resolved, and there is no RRMS activity. A 38-year-old woman with RRMS since 2016, treated with fingolimod since 2018, developed an axillary lymph node in 2022, which was diagnosed as breast cancer. She is currently undergoing chemotherapy for oncology, with no RRMS activity. dngjebpfee (vtckqzejol )
Positive
29 Feb 2024
Not Applicable
Multiple Sclerosis
CD4+ | CD8+ positive | human herpes virus 8
1
axybgmijuf(fznantkjqd) = One 56-year-old male patient with relapsing remitting MS treated with fingolimod who developed KS was identified. At the time of KS diagnosis, he had been treated with fingolimod for 9.5 years, and prior to fingolimod was treated with interferon beta-1a for 10 years. He developed a suspicious skin lesion which was biopsied and consistent with KS. Testing for HIV was negative, and CT scans of the chest, abdomen, and pelvis showed no signs of malignancy. His absolute CD4 count at time of KS diagnosis was 213 cell/mm3, and absolute lymphocyte count (ALC) was 0.72 cell/mm3 with a nadir of 0.44 cell/mm3 three years prior. mmfbxnolap (grtgobtcnp )
Positive
29 Feb 2024
Not Applicable
-
afnxiultmp(jydeyfcadg) = maqbpgpysy sgpmpbianm (fktyrfjwyg )
Positive
30 Sep 2023
afnxiultmp(jydeyfcadg) = unlpzrnfvj sgpmpbianm (fktyrfjwyg )
Not Applicable
-
cgmgevoaal(zfaxzgruwu) = xbepxqcqup tstaeblpul (hffjvxovbe )
-
30 Sep 2023
(Control)
cgmgevoaal(zfaxzgruwu) = bhqzmnwvzi tstaeblpul (hffjvxovbe )
Not Applicable
323
Fingolimod users
kyejzpzmyb(niwsacnyvb) = hvtlgzdzuf ugtqlovezh (kranpfsvna )
Negative
30 Sep 2023
Not Applicable
-
uaevgepwhi(rxgxhwlszz): HR = 1.08 (95% CI, 0.47 - 2.47)
-
30 Sep 2023
Not Applicable
58
hfyinwpjiz(zmtdwrxgdq) = cvyhvrahkq tytngnurno (dcxbpuknxi )
Positive
30 May 2023
hfyinwpjiz(zmtdwrxgdq) = xexoayfvkp tytngnurno (dcxbpuknxi )
Login to view more data

Translational Medicine

Boost your research with our translational medicine data.
Boost your research with our translational medicine data.

Deal

Boost your decision using our deal data.
Boost your decision using our deal data.

Core Patent

Boost your research with our Core Patent data.
Boost your research with our Core Patent data.

Clinical Trial

Identify the latest clinical trials across global registries.
Identify the latest clinical trials across global registries.

Approval

Accelerate your research with the latest regulatory approval information.
Accelerate your research with the latest regulatory approval information.

Regulation

Understand key drug designations in just a few clicks with Synapse.
Understand key drug designations in just a few clicks with Synapse.
Chat with Hiro
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free